Idexx Laboratories income statement

In fiscal 2025, Idexx Laboratories reported revenue of $4.30bn, up 10.4% on the year before, operating income of $1.36bn (a 31.6% margin) and net income of $1.06bn, or $13.08 per diluted share. Every line below comes from the company's 10-K and 10-Q filings; column headings link to the filing.

Income statement

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Idexx Laboratories: income statement, annual
Fiscal year	2009Dec 2009	2010Dec 2010	2011Dec 2011	2012Dec 2012	2013Dec 2013	2014Dec 2014	2015Dec 2015	2016Dec 2016	2017Dec 2017	2018Dec 2018	2019Dec 2019	2020Dec 2020	2021Dec 2021	2022Dec 2022	2023Dec 2023	2024Dec 2024	2025Dec 2025	LTMSept 2026
Revenue	1,032	1,103	1,219	1,293	1,377	1,486	1,602	1,775	1,969	2,213	2,407	2,707	3,215	3,367	3,661	3,898	4,304	4,662
Cost of revenue	505	525	572	594	621	670	712	800	872	972	1,041	1,136	1,326	1,363	1,471	1,519	1,644	1,738
Gross profit	526	579	647	699	756	816	890	975	1,097	1,242	1,366	1,571	1,889	2,004	2,190	2,379	2,660	2,924
Research and development	65	69	76	82	88	98	100	101	109	118	133	141	161	255	191	220	251	267
Selling and marketing	168	180	205	217	243	284	300	317	354	387	418	434	487	525	566	589	644	683
General and administrative	117	127	129	138	158	174	183	207	221	245	261	301	310	326	336	442	405	468
Operating income	176	204	236	263	267	260	300	350	413	491	553	695	932	899	1,097	1,128	1,360	1,506
Interest expense	2	2	4	4	5	15	29	32	37	35	31	33	30	40	42	31	39	35
Provision for credit losses	—	—	—	—	—	—	—	—	—	—	1	5	1	6	6	7	8	10
Income before tax	175	202	234	261	263	247	273	322	381	458	522	662	903	860	1,061	1,110	1,324	1,479
Income tax	52	61	73	82	75	65	81	100	118	81	94	80	158	181	216	222	265	297
Net income	122	141	162	178	188	182	192	222	263	377	428	582	745	679	845	888	1,059	1,182
Diluted EPS	$1.00	$1.19	$1.39	$1.58	$1.74	$1.79	$2.05	$2.44	$2.94	$4.26	$4.89	$6.71	$8.60	$8.03	$10.06	$10.67	$13.08	$14.82
Diluted shares (average)	121m	119m	116m	112m	108m	102m	94m	91m	90m	88m	88m	87m	87m	85m	84m	83m	81m	80m
EBITDA	226	250	284	315	321	319	369	428	496	575	641	791	1,037	1,011	1,212	1,258	1,505	1,664

US$ millions unless shown otherwise. Fiscal quarters.

Idexx Laboratories: income statement, quarterly
Quarter	2024 Q4Dec 2024	2025 Q1Mar 2025	2025 Q2Jun 2025	2025 Q3Sept 2025	2025 Q4Dec 2025	2026 Q1Mar 2026	2026 Q2Jun 2026	2026 Q3Sept 2026
Revenue	954	998	1,109	1,105	1,091	1,141	1,217	1,214
Cost of revenue	384	375	415	422	432	418	437	450
Gross profit	571	623	695	683	658	723	779	764
Research and development	58	59	62	63	67	66	65	69
Selling and marketing	150	156	161	159	167	175	171	170
General and administrative	101	92	99	106	109	119	117	123
Operating income	262	317	373	355	316	363	426	402
Interest expense	7	8	11	11	9	8	10	7
Provision for credit losses	2	3	1	2	2	4	2	2
Income before tax	256	310	362	345	307	355	417	399
Income tax	40	67	68	70	59	77	79	82
Net income	216	243	294	275	248	278	338	317
Diluted EPS	$2.62	$2.96	$3.63	$3.40	$3.09	$3.47	$4.27	$4.01
EBITDA	295	351	409	391	354	400	467	443

EBITDA is operating income plus depreciation and amortisation. EPS and share counts are restated for stock splits. A dash means the company did not report the line for that period; expense lines are shown as reported, so they need not add up to the totals when a company reports other items between them.

Compare with peers

Head to head: DXCM vs IDXX BLCO vs IDXX IDXX vs RMD

More: Health Care Equipment stocks compared, Health Care sector, rankings of US companies

Figures from Idexx Laboratories's SEC filings (10-K and 10-Q), retrieved November 2, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Idexx Laboratories.